Stem cell biotech stays afloat
Embryonic stem cell biotech company linkurl:Advanced Cell Technology;http://www.advancedcell.com/ (ACT), announced today (Oct. 7) that it will be selling off $500,000 in convertible bonds in the next three months, following the company's linkurl:disclosure;http://www.the-scientist.com/blog/display/54884/ this summer that it was experiencing financial troubles. The Massachusetts-based company told linkurl:__Mass High Tech__;http://www.masshightech.com/stories/2008/10/06/daily29-Advanced-Cell-Tec
Bob Grant
From 2017 to 2022, Bob Grant was Editor in Chief of The Scientist, where he started in 2007 as a Staff Writer.
View Full Profile.
Learn about our Editorial Policies.
| 1 min read
Register for free to listen to this article
Listen with Speechify
0:00
1:00
Share
Interested in reading more?
The Scientist ARCHIVES
Become a Member of
Receive full access to more than 35 years of archives, as well as TS Digest, digital editions of The Scientist, feature stories, and much more!
Already a member? Login Here
Meet the Author
Bob Grant
From 2017 to 2022, Bob Grant was Editor in Chief of The Scientist, where he started in 2007 as a Staff Writer.View full profile
Share
